Investigational drug · Phase 2
ALDP001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Seasonal Allergic Rhinitis (SAR).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ALDP001"
First trial start
2025
Oct 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALDP001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Seasonal Allergic Rhinitis (SAR)
Approved drugs for the same conditions: Allergies (allergic rhinitis)
Largest trials
Live from ClinicalTrials.gov: studies naming "ALDP001" as an intervention, largest first.
- A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen ExposurePivotal-lookingRecruiting
Alixer Nexgen Therapeutics LimitedIndustry
NCT07219849 · 164 participants (planned) · Start Oct 17, 2025 · Primary completion Apr 2026
Drug: ALDP001 Nasal Spray; Placebo Nasal spray · For: Seasonal Allergic Rhinitis (SAR)
Sites: Mississauga, Canada
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Seasonal Allergic Rhinitis (SAR)
- StapokibartPhase 34 trials
Chengdu Kangnuoxing Biopharma,Inc. · Seasonal Allergic Rhinitis (SAR), Bullous Pemphigoid (BP), Prurigo Nodularis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.